Patent classifications
A61P25/04
Use of placental stem cells in treatment of acute kidney injury
Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI).
Tri-molecular complex of natural compounds
The invention discloses a composition exhibiting enhanced bioavailability comprising tri-molecular complex of a natural compound or a natural compound containing component, a divalent or tri-valent metal ion and a phospholipid embedded in natural matrix. The composition of the invention further exhibits a sustained release profile for the natural compound or natural compound containing component. The invention further discloses a process for manufacturing the tri-molecular complex containing composition.
Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
Large molecular weight alginates which are covalently modified to store and release nitric oxide, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both planktonic and biofilm-based bacteria.
Novel Therapeutic Uses of Mu-Opiate Receptor Peptides
The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.
THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES
The present disclosure provides for treating neurodegenerative diseases comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.
USE OF CGRP RECEPTOR ANTAGONISTS IN NEUROPROTECTION AND NEUROLOGICAL DISORDERS
Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.
PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES
A process for preparing a compound of Formula (1a):
##STR00001##
or a pharmaceutically acceptable salt thereof.
Heterocyclic compounds and uses thereof
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
Aqueous pharmaceutical formulation of tapentadol for oral administration
An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
Extended buprenorphine transdermal delivery compositions and methods for using the same
Aspects of the invention include extended transdermal delivery devices for delivering buprenorphine to a subject for an extended period of time, where the transdermal delivery devices include buprenorphine, an α-hydroxy acid and a pressure sensitive adhesive. In certain instances, buprenorphine, α-hydroxy acid and the pressure sensitive adhesive are provided as a single matrix layer formulation. Also provided are methods of using the subject extended transdermal delivery devices, as well as kits containing the extended transdermal delivery device.